![](https://www.endotext.org/wp-content/uploads/2018/06/etx-difuse-hormones-ch5-fig9.png)
Figure 9. This figure compares the progression free survival (PFS) in patients with advanced metastatic PNETs treated with sunitinib in the SUN1111 trial (173) compared to everolimus in the RADIANT- 3 trial (177). While the PFS are similar, there are significant differences in the side effects; thus, choices need to be individualized.